Abstract:Introduction: The selective serotonin and norepinephrine reuptake inhibitor venlafaxine is among the most prescribed antidepressant drugs worldwide and, according to guidelines, its dose titration should be guided by drug-level monitoring of its active moiety (AM) which consists of venlafaxine (VEN) plus active metabolite O-desmethylvenlafaxine (ODV). This indication of therapeutic drug monitoring (TDM), however, assumes a clear concentration/effect relationship for a drug, which for VEN has not been systematically explored yet. Objectives: We performed a systematic review and meta-analysis to investigate the relationship between blood levels, efficacy, and adverse reactions in order to suggest an optimal target concentration range for VEN oral formulations for the treatment of depression. Methods: Four databases (MEDLINE (PubMed), PsycINFO, Web of Science Core Collection, and Cochrane Library) were systematically searched in March 2022 for relevant articles according to a previously published protocol. Reviewers independently screened references and performed data extraction and critical appraisal. Results: High-quality randomized controlled trials investigating concentration/efficacy relationships and studies using a placebo lead-in phase were not found. Sixty-eight articles, consisting mostly of naturalistic TDM studies or small noncontrolled studies, met the eligibility criteria. Of them, five cohort studies reported a positive correlation between blood levels and antidepressant effects after VEN treatment. Our meta-analyses showed (i) higher AM and (ii) higher ODV concentrations in patients responding to VEN treatment when compared to non-responders (n = 360, k = 5). AM concentration-dependent occurrence of tremor was reported in one study. We found a linear relationship between daily dose and AM concentration within guideline recommended doses (75-225 mg/day). The population-based concentration ranges (25-75% interquartile) among 11 studies (n = 3200) using flexible dosing were (i) 225-450 ng/ml for the AM and (ii) 144-302 ng/ml for ODV. One PET study reported an occupancy of 80% serotonin transporters for ODV serum levels above 85 ng/ml. Based on our findings, we propose a therapeutic reference range for AM of 140-600 ng/ml. Conclusion: VEN TDM within a range of 140 to 600 ng/ml (AM) will increase the probability of response in nonresponders. A titration within the proposed reference range is recommended in case of non-response at lower drug concentrations as a consequence of VEN's dual mechanism of action via combined serotonin and norepinephrine reuptake inhibition. Drug titration towards higher concentrations will, however, increase the risk for ADRs, in particular with supratherapeutic drug concentrations.

A Review on Analytical Method for Determination of Venlafaxine HCl in Bulk and Pharmaceutical dosage form

Treatment of Depressive Outpatient with Venlafaxine:An Open Clinical Trial

Expert consensus for clinical appliance of venlafaxine controlled release formulation

The efficacy and safety of venlafaxine XR in treating patients with major depression in a multicenter,open-label, 16 week study

Solid-state evaluation and polymorphic quantification of venlafaxine hydrochloride raw materials using the Rietveld method

A Comprehensive Review of Analytical Methods Developed for Selective Serotonin Reuptake Inhibitors (SSRIs)

Determination of Venlafaxine Hydrochloride in Venlafaxine Hydrochloride Sustained-Release Tablets by HPLC

[An Improved Novel Method of Venlafaxine Synthesis].

Development and Evaluation of Venlafaxine Hydrochloride Tablets for Oral Drug Delivery Technology

Psychopharmacological properties and therapeutic profile of the antidepressant venlafaxine

Multiple-reaction monitoring (MRM) LC–MS/MS quantitation of venlafaxine and its O-desmethyl metabolite for a preclinical pharmacokinetic study in rabbits

Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors

Venlafaxine's therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysis

Venlafaxine Caffeic Acid Salt: Synthesis, Structural Characterization, and Hypoglycemic Effect Analysis

Design and evaluation of cost-effective oro-dispersible tablets of venlafaxine hydrochloride by effervescent method

Isolation of Antidepressants and Their Metabolites from Saliva Using Supported Liquid Extraction (SLE)

Liquid Chromatography Tandem Mass Spectrometry Assay for Simultaneous Determination of Venlafaxine and Its Active Metabolite in Human Plasma and Its Application to a Bioequivalence Study

Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence

Development of a Novel Second-Generation Polyester Dendritic Functionalized Graphene Oxide for Efficient Pipette Tip Micro Solid-Phase Extraction and Detection of Venlafaxine and Desvenlafaxine in Urine

Metabolic Effects of Two Different Doses of Venlafaxine Therapy on Rats